The DEA Gave Kratom Sellers 5 Weeks. Your Corner Store Kratom Isn’t What They’re Talking About.

The DEA drew a line inside a plant, and almost nobody covering the story is keeping the two sides of that line straight.

On July 1, the DEA announced its intent to temporarily place 7-hydroxymitragynine — 7-OH for short — and a list of related synthetic compounds (including two lab-made derivatives called MGM-15 and MGM-16) into Schedule I for two years, the same legal category as heroin. The order is expected to take effect around August 5, giving manufacturers roughly five weeks of runway. If you use kratom to manage opioid withdrawal, chronic pain, or as a lower-risk substitute while you work toward reducing opioid use, the plain-language version you need is this: naturally occurring kratom leaf and extract — the kind sold as green, red, or white vein powder, at the concentrations it grows at — is explicitly carved out of this order. What the DEA is targeting is a newer category of products that concentrate or chemically synthesize 7-OH, one of kratom’s dozens of natural alkaloids, to levels far above what the plant produces on its own, creating something closer to a synthetic opioid than to traditional kratom.

That distinction matters because 7-OH is not a fringe chemistry footnote. It’s the compound inside kratom that binds most strongly to opioid receptors, and concentrated 7-OH products — sold as shots, tablets, and “extra strength” extracts in vape shops and gas stations — have driven most of the acute overdose and dependence cases that have made kratom a public-health flashpoint over the past two years, according to the Congressional Research Service’s summary of the action. Whole-leaf kratom, used the way it’s been used for generations in Southeast Asia and increasingly by Americans self-managing opioid tapering, isn’t the same product, and the DEA’s order says so directly.

That nuance is exactly what’s getting lost. Advocacy groups on both sides are already split — kratom trade associations that spent years distancing whole-leaf products from 7-OH shots worry retailers will pull all kratom off shelves rather than parse the difference under a five-week deadline, while public health advocates who’ve tracked 7-OH poison-control calls argue the order doesn’t go far enough, fast enough. Caught in the middle are the people who’ve told researchers, in survey after survey, that kratom is the thing that got them off something worse — for whom “kratom just got scheduled” lands as a headline before “only the synthetic version” does.

If you’re one of those people: nothing in this order makes possessing or buying whole-leaf kratom illegal. What it does is squeeze the supply chain hard enough, in five weeks, that confusion at the retail level is the likely near-term reality — expect some stores to pull all kratom products rather than sort synthetic from whole-leaf inventory in time. If a source you rely on disappears from a shelf this month, that’s a supply-chain reaction to a five-week deadline, not a sign that what you’ve been using became a federal crime. Ask before you assume, and if kratom has been part of how you’ve stayed off something more dangerous, that’s a conversation worth having with a provider now, while the picture is still shifting rather than after a source runs dry.